|
December 2007
FDA has questions on Glaxo cervical cancer vaccine
December 17, 2007
LONDON (Reuters) - GlaxoSmithKline Plc's cervical cancer vaccine Cervarix faces a delay in winning approval in the United States, putting it further behind Merck & Co Inc's rival product Gardasil, which is already available.
Combo therapy with Tykerb fights brain metastases
December 17, 2007
LONDON (Reuters) - A combination drug treatment that includes Tykerb, know generically as lapatinib, appears to be able to fight breast cancer that has spread to the brain, GlaxoSmithKline Plc announced Sunday.
Report sees 7.6 million global 2007 cancer deaths
December 17, 2007
WASHINGTON (Reuters) - About 7.6 million people will die this year worldwide from various types of cancer, with lung cancer -- heavily driven by smoking -- killing 975,000 men and 376,000 women, the American Cancer Society said on Monday.
Arimidex most effective in breast cancer study
December 17, 2007
NEW YORK (Reuters Health) - After approximately 8 years, postmenopausal women with hormone-sensitive breast cancer who received (Arimidex), generically known as anastrazole, had a lower risk of recurrence than women taking tamoxifen, investigators reported at the annual meeting of the San Antonio Breast Cancer Symposium.
HER-2-positive breast cancer tied to hormone status
December 17, 2007
NEW YORK (Reuters Health) - Breast cancer patients whose tumors test positive for the protein HER-2 and test negative for hormone receptors have a high risk of treatment failure after chemotherapy -- and the most common site of cancer recurrence after treatment failure is the brain, Mayo Clinic researchers reported at the San Antonio Breast Cancer Symposium.
Chemotherapy after surgery for stage II CRC can improve survival
December 14, 2007
NEW YORK (Reuters Health) - Treatment with adjuvant fluorouracil and folinic acid following resection of node-negative stage II colorectal cancer (CRC) provides a "small but definite benefit" in survival, an international team reports in the December 15th issue of The Lancet.
Long-term data show superiority of anastrazole over tamoxifen in early breast cancer
December 14, 2007
NEW YORK (Reuters Health) - Approximately 8 years of follow-up data show that, for postmenopausal women with hormone-sensitive breast cancer, anastrazole (Arimidex) is associated with a lower risk of recurrence than tamoxifen (Novaldex), investigators reported at the annual meeting of the San Antonio Breast Cancer Symposium being held this week.
High-dose chemo with HSCT outdated for breast cancer
December 14, 2007
NEW YORK (Reuters Health) - No overall survival benefit is gained with high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT) for women with early breast cancer and multiple positive nodes.
Sunitinib treatment requires close monitoring for cardiotoxicity
December 13, 2007
NEW YORK (Reuters Health) - Treatment with sunitinib, a tyrosine kinase inhibitor used for metastatic renal cell cancer and gastrointestinal stromal tumors (GIST), can cause hypertension and left ventricular dysfunction and patients should therefore be watched closely, especially if they have a history of heart disease, new research shows. Investigational agent eliminates resistance in CML
December 12, 2007
NEW YORK (Reuters Health) - A new Abl kinase inhibitor that eliminates resistance to nilotinib and dasatinib in the treatment of chronic myeloid leukemia (CML) in mice and in human cell lines was described this week at the 49th annual meeting of the American Society of Hematology in Atlanta, Georgia.
Ixabepilone addition helpful in metastatic breast cancer
December 11, 2007
NEW YORK (Reuters Health) - Ixabepilone, the first of a new class of antineoplastic agents, in combination with capecitabine is more effective than capecitabine alone in patients with refractory metastatic breast cancer, according to researchers.
Scientists discover how BRCA1 gene causes cancer
December 11, 2007
CHICAGO (Reuters Health) - Mutations in the BRCA1 breast cancer gene appear to be linked with the loss of a protein important for putting the brakes on cell growth, a finding that could lead to new therapies, researchers said on Sunday.
Leukemia vaccine triples event-free survival
December 11, 2007
NEW YORK (Reuters Health) - A peptide vaccine against leukemia-associated antigens more than triples event-free survival, from 2.4 months with conventional therapy to 8.7 months, investigators at the University of Texas MD Anderson Cancer Center in Houston reported this week at the 49th annual meeting of the American Society of Hematology underway in Atlanta, Georgia.
Extended adjuvant aromatase inhibitor therapy beneficial in breast cancer
December 11, 2007
NEW YORK (Reuters Health) - Women with breast cancer who complete 5 years of tamoxifen therapy derive significant benefit from an additional 3 years of treatment with the aromatase inhibitor anastrozole, results of the Austrian Breast and Colorectal Study suggest.
Novartis says Glivec stops leukaemia progression
December 10, 2007
ZURICH (Reuters) - Novartis's Glivec/Gleevec (imatinib) stopped cancer progression in all the patients between years 5 and 6 of a pivotal leukaemia trial, according to data presented on Sunday at the American Society of Hematology (ASH) meeting in Atlanta.
Reduced-intensity conditioning safe with stem cell transplant in CML
December 10, 2007
NEW YORK (Reuters Health) - A reduction in intensity of the conditioning regimen prior to hematopoietic stem cell transplantation does not significantly reduce overall survival and allows adequate disease control in chronic myelogenous leukemia (CML), researchers report in the November 1st issue of Blood.
Novartis says Tasigna effective in early leukaemia
December 10, 2007
ZURICH (Reuters) - Novartis's cancer drug Tasigna (nilotinib) is effective as a first-line treatment for patients with newly diagnosed chronic myeloid leukaemia (CML), according to data presented on Sunday.
Gentler chemo helps patients survive lymphoma
December 10, 2007
WASHINGTON (Reuters) - A gentler chemotherapy regimen may help some lymphoma patients better tolerate and benefit from bone marrow transplants, and the combination could even cure them, U.S. doctors reported on Monday.
Celgene's Revlimid delays myeloma progression
December 10, 2007
BOSTON (Reuters) - Celgene Corp said on Sunday that its cancer drug Revlimid in combination with the steroid dexamethasone helped newly diagnosed patients with multiple myeloma stave off their disease longer than those who took dexamethasone alone.
Velcade boosts survival in multiple myeloma
December 10, 2007
BOSTON (Reuters) - Millennium Pharmaceuticals Inc said on Sunday that newly diagnosed patients with multiple myeloma who took its drug Velcade in combination with a standard regimen had significant improvement in overall survival, compared to patients who took the standard regimen alone.
Drug works in non-Hodgkin's lymphoma: study
December 10, 2007
NEW YORK (Reuters) - Cephalon Inc's experimental cancer drug Treanda appeared to be effective in patients whose non-Hodgkin's lymphoma (NHL) had progressed during or following treatment with Rituxan in a late-stage study, the company and researchers said on Saturday.
Experimental drug works in type of leukemia
December 10, 2007
NEW YORK (Reuters) - Cephalon Inc's experimental cancer drug Treanda was significantly more effective than a common chemotherapy agent in helping patients with chronic lymphocytic leukemia (CLL) who had not received prior treatment achieve remission, according to a late-stage study.
Genotype tied to success of breast cancer therapy with tamoxifen
December 7, 2007
NEW YORK (Reuters Health) - Variants in genes CYP2D6 and CYP2C19 encoding P450 enzymes can predict therapy response or failure in patients with estrogen receptor-positive breast cancer treated with tamoxifen, according to German researchers.
Childhood cancer mortality falling in US, but racial disparities seen
December 6, 2007
NEW YORK (Reuters Health) - From 1990 to 2004, death rates in children with cancer in the US fell from 34.2% to 27.3%, according to findings released Thursday in the Morbidity and Mortality Weekly Report.
US panel rejects Avastin for use in breast cancer
December 6, 2007
GAITHERSBURG, Maryland (Reuters) - Cancer drug Avastin should not be approved to treat women with breast cancer, a U.S. advisory panel recommended on Wednesday.
|
